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| INTRODUCTION
Lung cancer remains the most frequently diagnosed cancer and a leading cause of cancer-related mortality worldwide. 1 Due to late presentation of clinical symptoms and limited screening programmes, as many as 57% of patients diagnosed with lung cancer present with metastasis. 2 Histologically, approximately 85% of all new lung cancer cases are classified as nonsmall cell lung cancers (NSCLC), 10% are small cell lung cancer (SCLC) and 5% account for other variants. 3 Most NSCLC can be grouped into 3 main categories: Squamous Cell Carcinoma, Adenocarcinoma and Large Cell Carcinoma histo-subtypes. Besides histological, clinical and demographic information, a wide range of data ranging from genomics, proteomics, immunohistochemistry and imaging must be integrated by physicians when developing personalized treatment plans for patients which can be challenging and lead to unfavourable outcomes. Furthermore, there are a number of factors that limit timely access to these tests, including high cost and late availability in the patient care continuum. sis and interpretation of data by machine algorithms that allow classification, prediction and segmentation of information to provide insights not readily available to the human eye or cognition. Although ML algorithms were developed over 20 years ago, the recent surge in the application of algorithms in health care has demonstrated a significant potential for their use in advancing cancer care.
Given the increased use of AI in cancer care, this article will offer a review of the ML applications that are being developed for detection and treatment of NSCLC as well as current challenges facing clinical adaptation.
| INITIAL EVALUATION OF LUNG CANCER PATIENTS
In current clinical practice, cancer diagnosis begins when a patient presents with a suspicious lesion on screening or signs and symptoms considered consistent with a diagnosis of lung cancer. Imaging modalities used to evaluate the presence and extent of cancer include computed tomography (CT), single-photon emission computed tomography (SPECT), magnetic resonance imaging (MRI) and 18F-fluorodeoxyglucose positron emission tomography-computed tomography ( 18 F-FDG PET-CT). These radiological procedures are partially quantitative in nature and are subjectively integrated with the clinical picture. Information about lesions that are visible to the human eye is readily accessible to radiologists; however, it is reasonable to question if there is additional information present in an image.
In an attempt to increase the information obtained from medical images and assist radiologists, computer-aided diagnosis (CAD) systems have been developed which are classified into two groups: computer-aided detection (CADe) systems that help in determining the location of lesions in medical images and computer-aided diagnosis (CADx) systems used for the distinction between benign and malignant tumours. 5 Both CADe and CADx systems are breakthroughs and important areas of research, but neither is as yet consistently accurate and thus widespread clinical adoption is lacking. 6 The slow integration of CAD into clinical workflow may be related to the misalignment of technology and clinical needs. CADe systems, for example, are able to differentiate lung wall, parenchyma and bronchioles from nodules while detecting solid, nonsolid and cavitary nodules with a sensitivity of up to 89%. CADe is therefore useful for detecting nodules, but not for nodule characterization. 7 CADx on the other hand is useful for characterization, but not for detection of tumours. For example, CADx systems use either morphological characteristics that are engineered from experts' perceptions, intensity values and image textures that are mathematically extracted quantitative descriptors to classify malignant vs. benign nodules. 8 The quantifiable visual features such as intensity, morphology and surface texture are now commonly referred to as radiomic features. 9 CADe systems are useful in detecting the nodules but do not characterize them. While CADx systems are good at characterization, they lack in their ability to detect tumours. New approaches that use ML methods to detect and diagnose lung nodules are able to detect and diagnose tumours as small as 3 mm. These results are promising as they offer radiologists an automated tool for detection and diagnosis. However, image processing techniques are constantly under review for their ability to characterize nodules from an image. 10 The clinical information that ML algorithms aim to extract and interpret include calcification pattern of the nodule, internal structure, margins, lobulation, sphericity, speculation and texture. This information is critical to patient care, and future work in the field will require conducting clinical trials of the proposed methods and verifying their performance in the real world. The ML algorithms used for feature extraction still need to be examined to determine the optimal values to be used to achieve this goal.
3 | DIAGNOSIS 3.1 | Machine learning and the "Optical
Biopsy"
For centrally located lung cancers, bronchoscopy is an essential tool for diagnosis. One advantage of using bronchoscopy over other imaging techniques is that diagnostic specimens can be obtained simultaneously using biopsy. For mediastinal tumours, biopsies are obtained using endobronchial ultrasonography (EBUS) and transbronchial needle aspiration (TBNA). As for the peripheral lesions with a negative bronchoscopy, a transthoracic needle aspiration (TNA) can be obtained. Until recently, the early diagnosis of lung cancer was dependent on inspecting the bronchial mucosa during an endoscopic procedure and pathological analysis on biopsies obtained. However lately, some techniques such as fibered confocal fluorescence microscopy (FCFM) are emerging that extend this field of exploration to the distal lung and to the cellular level. 11 This technique uses 2 mm working channels and produces in vivo endomicroscopic images of the human respiratory tract in real time. With the use of ML methods, image features obtained by FCFM can be extracted and used to discriminate benign from malignant tumours. In vivo applications of this method provide real-time analysis of lesions achieving recognition rates as high as 90%. 12 The technique is promising and is currently being investigated for its use in recognizing the different grades of progression of the precancer bronchial lesions such as metaplasia/dysplasia/carcinoma in situ. The video taken can also be scored for image characteristics that are predictive of cancer and other lung pathologies such as sarcoidosis and interstitial lung disease. 13 The challenge that lies ahead is being able to discriminate features specific to each grade and disease. The technology itself also poses a limitation considering the microscopic evaluation that it provides. Evaluating the entire lung one microscopic area at a time is not practical, and digital image analysis might be the solution to this. Further research is required to determine whether this technique can diagnose other diseases that involve the bronchial mucosa and build image libraries for ML methods to be used. The technique is promising as it might offer an alternative to lung biopsies in the future. 12 
| Machine learning in histopathology
Patients with lung cancer often present with advanced, inoperable disease; therefore, biopsy specimens are generally limited in size because the entire tumour cannot be removed. 14 The presence of ambiguous histological features makes it difficult to distinguish squamous cell carcinoma from adenocarcinoma, particularly in poorly differentiated tumours. To deal with such a problem, comprehensive and automated diagnostic strategies for histologic subtyping of NSCLC biopsy specimens are being established by applying ML methods in immunohistochemistry (IHC). 14 Most of the recent studies have been focused on identifying highly sensitive and specific IHC markers that provide an accurate histological subtyping of NSCLC. The consensus of these studies is the use of a combination of IHC panels that include as many as 3-6 markers and/or mucin staining. Koh et al's study describes a comprehensive diagnostic strategy for histologic subtyping of NSCLC biopsy specimens using a reliable and minimal IHC panel. 15 To establish this goal, the group employed two machine learning methods, a decision tree and a support vector machine (SVM) on 30 small biopsy cases of NSCLC that showed ambiguous morphology. The decision tree model showed that the combination of two markers, such as p63 and CK5/6, in addition to the 3-marker IHC panel (ie, TTF-1, Napsin A and p40) yielded the highest accuracy of approximately 72%. With the recent improvement in highthroughput whole-slide scanning technologies and image computing, ML is poised to make histology slide analysis and classification a new source of large data sets for precision oncology that may be integrated with predictive or prognostic information derived from radiomic analysis performed at tissue scale using routine clinical imaging. 16 Given the large volume of patients and slides to analyse, pathologists will be able to harness automated highthroughput whole-slide scanning that can expedite workflow while minimizing inter-rater variability. However, the application of ML in clinical pathology is not yet widespread. Pathologists will continue their mastery of the microscope to oversee machine-based interpretation and for the histology slides to remain an essential part of the"-omic data" for personalized therapy.
| Machine learning in NSCLC genomic classification
Multiple molecular abnormalities affecting oncogenes and tumour suppressor genes have been described in NSCLC. 16 Identifying the underlying genomic subtype of lung cancer can be used to propose a specific targeted therapy. For example, mutations in the epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) receptor are notable in NSCLC because they present molecular targets for tailored treatment options.
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The gene expression profile for subtypes of NSCLC has been established using microarrays. 18, 19 These genes are used to identify subtypes and are now used as biomarkers for NSCLC. The microarray data that are used to identify genetic subtypes of NSCLC can be used to train ML algorithms to better understand genomic pathways. For example, adenocarcinomas can be identified using only microarray data which can also be used to train ML algorithms to identify other potential biomarkers of NSCLC. 20 Moreover, there are multiple examples of ML classifiers that have been used to predict cancer subtype, tumour growth and metastatic potential. 21 As genomic data increase exponentially with the commercialization of nextgeneration sequencing and the performance of these algorithms improves, clinicians will be able to better characterize NSCLC based on genomic data. 22 
| MACHINE LEARNING IN PROGNOSIS
Survival outcomes vary for patients with adenocarcinoma or squamous cell carcinoma, and predicting survival for these distinct disease entities is challenging. To predict prognosis, histologic assessment of well-differentiated adenocarcinoma or squamous cell carcinoma in combination with molecular testing has been described. 23 Yu et al demonstrated that quantitative morphological features extracted from histological slides can predict patient survival. 24 The features are not detectable by manual inspection, but through the use of ML methods, it is possible to RABBANI ET AL.
identify features that correspond to survival. The group identified the most consistent features for classification and were able to predict prognosis of cancers with diverse histopathology patterns. When the group validated the survival predictive framework with a tissue microarray (TMA) database, they achieved a P value of .036 for both tumour types, adenocarcinoma and squamous cell carcinoma. Histopathology slides are routinely collected and can contribute to enhancing precision oncology. Moreover, Mi et al extracted dozens of predictive clinical and PET-based features associated with positive treatment outcomes. Through the use of hierarchical forward selection methods (HFS), the predictive accuracy of feature selection was 100% and 94% when tested against 2 databases.
25 These prognostic studies are helpful as they contribute to enhancing the quality of care. However, both the clinical utility and the validity of combining quantitative features from both immunochemical stained images and molecular data remain to be established in prospective trials. 26 This will be a critical step moving forward if computer-aided detection, diagnosis and clinical decision support systems are to be adopted in clinical settings. ML is highly dependent on the quality of data used to train the algorithm. The limitations that exist in the data collection process are inconsistent sampling and labelling of data. Understanding the problem or question which the algorithm will address is essential. For this reason, it is important to focus not only on validating the quantity and quality of data but to consider the data scientists' needs to create robust and consistent tools that can be trusted. 26 
| TREATMENT PERSONALIZATION IN RADIATION ONCOLOGY
In advanced-stage NSCLC, surgery is often not possible and chemoradiation is the standard of care. Radiation oncology is an attractive area for the incorporation of ML tools for several reasons. Radiotherapy systems generate large amounts of well-curated data from each patient with frequent CT scans, the data quality is exceptionally high and departments often use digital records and verification systems that store all the information regarding treatment history. Raw data provide detailed information on dosevolume histograms, treatment volumes, the time between each fraction, overall treatment time, dose rate and images produced by onboard systems. Using this data, ML systems can be designed to automatically select everything from the optimal angle for the radiation beam to dose-volume histogram predictions. 23, 27 Data can further be used to track the levels of radiation and toxicity, to aid in the development of clinical decision support tools and prevent radiation-induced complications such as pneumonitis. 28 Overall, the exploitation of this data can be used to create integrative predictive models that offer personalized radiation treatments with safety and efficiency. 29 Coroller et al demonstrated predictive radiomic features for treatment response using CT data. 33 However, the challenges of immunotherapy are dynamic. Once patients are started on an immunotherapy, the subsequent tumour response is often difficult to assess using standard criteria (such as RECIST or CHOI). Atypical response or pseudoprogression are hard to differentiate from failure to respond, 34, 35 and although progress is slowly being made using ML in other cancers, 36 it is lagging in lung cancer therapy. While advances in immunotherapy are coming at an accelerated pace, the paucity of data presents a challenge to applying ML algorithms to provide insights on treatment response. 37 
| MACHINE LEARNING AND IMMUNOTHERAPY

| TREATMENT SELECTION AND OUTCOME PREDICTION FOR SYSTEMIC THERAPIES
Systemic therapies continue to play a role in most stages of NSCLC. While a clear benefit for the use of adjuvant chemotherapy (ACT) in the treatment of stage I disease has yet to be proven, 38 complete surgical resection with adjuvant chemotherapy is the recommended approach for stage II NSCLC. 39 For late-stage patients, the treatment strategy may include a combination of radiotherapy, chemotherapy and surgical resection. Depending on the patient's molecular status, chemotherapy and/or targeted therapies such as EGFR tyrosine kinase inhibitors, ALK inhibitors or angiogenesis inhibitors are used. 40 In practice, it is valuable to obtain predictive factors before or during treatment, especially when the treatment choice is not yet confirmed. Future applications of ML algorithms in the treatment pathway can provide physicians with patient-specific predictive factors which will allow them to anticipate the outcomes of treatment they provide. For example, Chen et al used artificial neural networks (ANN) to model NSCLC survival. To do this, the group identified the ACT-correlated gene signatures and performed several types of ANN algorithms to construct the optimal ANN architecture for ACT benefit classification. 41 Then they assessed the reliability of their method by cross-data set validation. The 10-fold cross validation classification offered an accuracy of 65.71%. The results of their study showed that using gene signature profiles obtained from microarray analysis to predict adjuvant chemotherapy benefit in NSCLC is feasible. This could be an important step forward in avoiding treatment in patients when it is not needed and avoiding the waste of medical resources.
Other researchers have looked at the use of ML applications in predicting failure or death after the treatment. For example, Jochems et al looked at ML methods to predict early death in NSCLC patients following curative intent chemoradiation. 42 Similarly, Zhoe et al used ML to predict failure in early-stage NSCLC patients treated with stereotactic body radiation therapy. 43 Both groups, through the use of ML methods, developed prognostic models for early mortality or failure of treatment that can be used to inform patients about treatment options and optimize care. Kureshi et al investigated the role of multiple factors in predicting tumour response to EGFR-TKI therapy (erlotinib or gefitinib) in patients with advanced NSCLC. 44 The factors included clinical history, environmental risk factors and EGFR mutation status. The highest predictive accuracy of the data-driven decision support model reached 76%. This research is novel as it uses real-world patient data, and with more predictive features identified in the field, the accuracy is likely to improve. Their ML method has the potential to implement research findings directly into clinical practice and may provide healthcare professionals with individualized treatments based on each patient's classifiers and predictive features. Most outcome-prediction studies employ a small patient data set with limited heterogeneity. In the case of adjuvant chemotherapy after surgical treatment, the model presented here cannot be expanded to lung cancers that were not treated surgically, therefore limiting its application to only early-stage NSCLC. This is one example that demonstrates the limitation of ML algorithms. Further work needs to be carried out in incorporating data for the application of these methods to become adopted in the clinical pathway.
| FUTURE CHALLENGES
The use of AI to better understand and treat NSCLC is growing. The implementation of algorithms in clinical practice still faces obstacles. The standards and guidelines for regulation of artificial intelligence in healthcare remain to be established. The United States Food and Drug Administration is actively evaluating the use of algorithms in clinical practice.
There are significant legal and regulatory aspects to address. 45 Management of electronic health records can empower patients by enabling their access to their data. However, the current fragmented, decentralized state of medical records presents challenges to the application of algorithms in health care. Patient records exist in multiple forms such as free text, recorded speech or medical images and are rarely appropriately organized for computational analysis. Language and cultural barriers are also factors in the fragmentation of health data. Access to large amounts of well-organized high-quality data is essential for the application of machine learning in health care. Stakeholders may be unwilling to share data amongst each other due to responsibilities related to personal privacy laws or to a lesser extent misaligned commercial purposes. Although there are several proposed systems for distributed rapid learning healthcare, these efforts are still in their infancy. 46 Personal data privacy is another issue that must be addressed by the medical community and policy makers. 46 The harmonization of the regulatory framework is a critical step while ensuring personal data protection and compliance with legal matters.
Hacking also poses a threat; however, stakeholders must attempt to ensure that big data use does not lead to corruption or unethical use. This point is important due to the nature of private medical and genetic information which makes up a large portion of the data analysed in healthcare. Data ownership is another ethical hurdle that requires the protection and anonymization of information. The key to success will require the creation of policies that properly regulate the large federated data reserves. It is estimated that data for a single patient could amount to seven gigabytes, 47 including the genomic data. Health data security and accessibility are challenges for all institutions. The data must be easily accessible for those who need to access it, while security should be efficient to prevent inappropriate access. Strong user authentication methods should be in place to take into account the high-security constraints.
Traceability is important at all data processing steps. Linkage and coordination of medical records are steps that should not be overlooked and often require a third party that governs these procedures.
| CONCLUSION
Machine learning has become ubiquitous and indispensable for solving complex problems in most sciences. In this review, we have presented various applications of ML in the continuum of care of NSCLC patients. Doctors handle an enormous amount of data ranging from microlevel cellular features to macrolevel physiology and imaging studies, and more recently an increasing number of "-omics data". 47 Analysis of large amounts of data is complex, and machine learning is evolving into an essential tool to help doctors tackle this challenge to better understand their patients. For this reason, oncologists, radiologists and surgeons should continue to integrate machine learning tools into the clinical care continuum of NSCLC and become part of the digital revolution that has already taken place in business and technology sectors. Computer-assisted diagnosis will help identify early-stage disease and improve patient outcomes. The ultimate goal of machine learning is to provide a consistent, timely and personalized treatment strategy. With time, patients and doctors will benefit from the incorporation of ML methods in clinical practice once these tools have been validated in prospective studies.
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